Amgen (NASDAQ:AMGN) Price Target Raised to $360.00

02 Jan 2026, 01:08 by Jessica Moore · The Cerbat Gem

Amgen (NASDAQ:AMGN – Free Report) had its target price increased by Argus from $310.00 to $360.00 in a research note released on Tuesday morning, Marketbeat Ratings reports. They currently have a buy rating on the medical research company’s stock.

AMGN has been the subject of a number of other research reports. Wall Street Zen raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Monday, December 15th. Scotiabank began coverage on Amgen in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price objective on the stock. DZ Bank raised their target price on shares of Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. BMO Capital Markets boosted their target price on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. Finally, Bank of America increased their price target on Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research note on Friday, September 26th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Amgen has an average rating of “Moderate Buy” and an average target price of $335.35.

View Our Latest Report on AMGN

Amgen Price Performance

NASDAQ AMGN opened at $327.31 on Tuesday. The stock has a market capitalization of $176.25 billion, a price-to-earnings ratio of 25.29, a PEG ratio of 3.04 and a beta of 0.45. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. Amgen has a 1-year low of $257.05 and a 1-year high of $346.38. The business’s fifty day moving average price is $325.36 and its 200-day moving average price is $302.57.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.01 by $0.63. The business had revenue of $9.56 billion for the quarter, compared to analysts’ expectations of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The business’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period last year, the firm posted $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, equities analysts predict that Amgen will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be paid a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s payout ratio is presently 73.57%.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president directly owned 7,225 shares in the company, valued at $2,436,703.50. This represents a 30.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the transaction, the senior vice president directly owned 7,082 shares in the company, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 10,908 shares of company stock worth $3,674,966. Insiders own 0.76% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Legacy Investment Solutions LLC bought a new stake in shares of Amgen in the second quarter valued at about $27,000. CBIZ Investment Advisory Services LLC increased its position in Amgen by 1,214.3% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 85 shares during the period. Evelyn Partners Investment Management LLP bought a new stake in shares of Amgen in the 2nd quarter valued at about $32,000. Howard Hughes Medical Institute bought a new stake in shares of Amgen in the 2nd quarter valued at about $32,000. Finally, Quaker Wealth Management LLC lifted its position in shares of Amgen by 200.0% in the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock worth $34,000 after purchasing an additional 240 shares during the period. Institutional investors own 76.50% of the company’s stock.

About Amgen

(Get Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.